-
UPDATE: Leerink Swann Reiterates on Cempra Driven by Solithromycin Updates
Monday, November 18, 2013 - 12:14pm | 153Read More...In a report published Monday, Leerink Swann analyst Marko Kozul reiterated an Outperform rating on Cempra (NASDAQ: CEMP), and raised the price target from $11.00 to $17.00. In the report, Leerink Swann noted, “We are transitioning coverage of CEMP with a new DCF-based $17 price target (PT) and...
-
UPDATE: Leerink Swann Upgrades Cubist Pharmaceuticals Following Acquisition of TSRX
Thursday, September 26, 2013 - 10:23am | 148Read More...In a report published Thursday, Leerink Swann analyst Marko Kozul upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Market Perform to Outperform, and raised the price target from $57.00 to $76.00. In the report, Leerink Swann noted, “We are transitioning coverage of CBST with an...
-
Questcor Pharmaceuticals Plunges on U.S. Government Investigation
Monday, September 24, 2012 - 3:24pm | 326Read More...Last week, Questcor Pharmaceuticals (NASDAQ: QCOR) was among the most volatile stocks on the Nasdaq exchange after insurer Aetna (NYSE: AET) said that it was limiting coverage of the company's Athcar Gel drug used for the treatment of multiple sclerosis. The news sent QCOR plunging last Wednesday,...
